(TXG) 10X Genomics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US88025U1097

TXG: Instruments, Consumables, Software, Assays, Analyzers

10X Genomics Inc. (NASDAQ:TXG) is a leading life science technology company specializing in the development and commercialization of innovative instruments, consumables, and software for biological system analysis. The company operates globally, serving customers across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. Its product portfolio includes the Chromium platform, which enables single-cell and multiomic analysis through microfluidic chips, consumables, and instruments like the Chromium X Series. The Visium platform offers spatial gene expression and protein analysis solutions, including the Visium CytAssist instrument, which streamlines workflows for spatial biology applications. Additionally, the Xenium Analyzer allows researchers to detect RNA targets in fresh frozen or FFPE tissue sections while preserving cellular spatial information. The company serves a diverse range of customers, including academic institutions, government laboratories, and biopharmaceutical and biotechnology firms. Originally named 10X Technologies, Inc., the company rebranded as 10X Genomics Inc. in November 2014 and was incorporated in 2012. It is headquartered in Pleasanton, California.

From a technical perspective, TXG stock has shown declining momentum, with its SMA 20, 50, and 200 all below the last price of $8.43. This indicates bearish sentiment in the short to long term. The ATR of 0.63 reflects moderate volatility. Fundamentally, the company has a market cap of $997.39M, with a forward P/E of 196.08, suggesting high valuations relative to expected earnings. The P/B ratio of 1.47 indicates that the stock is trading at a premium to its book value. However, the negative RoE of -25.72% highlights ongoing profitability challenges.

Based on the technical and fundamental data, TXG is expected to face headwinds in the near term due to declining SMA trends and high valuations. The negative RoE and lack of profitability raise concerns about its ability to justify its forward P/E. While the companys innovative platforms position it well in the growing single-cell and spatial biology markets, investors should remain cautious given the current technical and fundamental challenges.

Additional Sources for TXG Stock

TXG Stock Overview

Market Cap in USD 997m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 2019-09-12

TXG Stock Ratings

Growth Rating -90.3
Fundamental -20.4
Dividend Rating 0.0
Rel. Strength -64.5
Analysts 3.76/5
Fair Price Momentum 4.81 USD
Fair Price DCF -

TXG Dividends

No Dividends Paid

TXG Growth Ratios

Growth Correlation 3m -87.8%
Growth Correlation 12m -90.3%
Growth Correlation 5y -86.1%
CAGR 5y -36.25%
CAGR/Max DD 5y -0.38
Sharpe Ratio 12m -1.41
Alpha -76.57
Beta 0.993
Volatility 78.91%
Current Volume 4978.5k
Average Volume 20d 3362.6k
What is the price of TXG stocks?
As of May 09, 2025, the stock is trading at USD 8.63 with a total of 4,978,545 shares traded.
Over the past week, the price has changed by +6.54%, over one month by +20.87%, over three months by -28.44% and over the past year by -65.97%.
Is 10X Genomics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, 10X Genomics is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -20.43 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TXG as of May 2025 is 4.81. This means that TXG is currently overvalued and has a potential downside of -44.26%.
Is TXG a buy, sell or hold?
10X Genomics has received a consensus analysts rating of 3.76. Therefor, it is recommend to hold TXG.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 8
  • Sell: 1
  • Strong Sell: 0
What are the forecast for TXG stock price target?
According to ValueRays Forecast Model, TXG 10X Genomics will be worth about 5.5 in May 2026. The stock is currently trading at 8.63. This means that the stock has a potential downside of -36.85%.
Issuer Forecast Upside
Wallstreet Target Price 15.3 76.9%
Analysts Target Price 20.1 133.4%
ValueRay Target Price 5.5 -36.8%